SGP (SpyGlass Pharma) Debt-to-Asset : 0.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $26.39
! 1 Warning Sign
View Full Analysis

What is SpyGlass Pharma Debt-to-Asset?

SpyGlass Pharma SGP -1.67% 12 Debt-to-Asset is 0.01 as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

SpyGlass Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. SpyGlass Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.63 Mil. SpyGlass Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $243.43 Mil. SpyGlass Pharma's debt to asset for the quarter that ended in Jun. 2026 was 0.01.

SpyGlass Pharma  (NAS:SGP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

SpyGlass Pharma Debt-to-Asset Related Terms

SpyGlass Pharma Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma Debt-to-Asset Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
Debt-to-Asset
0.00 0.17 0.01

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial 0.00 0.03 0.01 0.01 0.01

SGP vs RIGL, NGNE, OCS: Debt-to-Asset Comparison

For the Biotechnology subindustry, SpyGlass Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpyGlass Pharma Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where SpyGlass Pharma's Debt-to-Asset falls into.


SGP
12GF Score
SpyGlass Pharma Inc SGP
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

SpyGlass Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 1.582) / 115.866
=0.01

SpyGlass Pharma's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 1.632) / 243.433
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
SpyGlass Pharma (SGP) has a Debt-to-Asset of 0.01 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's Debt-to-Asset too high?
SpyGlass Pharma's current Debt-to-Asset is 0.01. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Debt-to-Asset compare to RIGL and NGNE?
SpyGlass Pharma's Debt-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. SpyGlass Pharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Debt-to-Asset is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.39
Price